ZEO ScientifiX is Moving Toward Its Goal of Transforming Healthcare Through Leading-Edge Research
ZEO ScientifiX (OTCQB:ZEOX), a South Florida-based clinical-stage biopharmaceutical company, is advancing its research program into Phase 2 clinical trials. The company recently completed successful Phase 1 trials for its flagship product, Zofin™, and is now seeking FDA approval for various diseases and chronic conditions.
ZEO's product pipeline includes Zofin™, derived from perinatal sources, and Patient Pure X™ (PPX™), an autologous biologic from a patient's peripheral blood. The company is also developing topical aesthetic and anti-aging applications in partnership with Exotropin,
With a projected market growth of 22.8% annually in regenerative medicine, ZEO aims to become an industry leader in biologic therapeutics. The company recently changed its name from Organicell Regenerative Medicine to better reflect its scientific research focus.
ZEO ScientifiX (OTCQB:ZEOX), un'azienda biofarmaceutica clinica con sede in Florida del Sud, sta portando avanti il suo programma di ricerca verso la fase 2 degli studi clinici. L'azienda ha recentemente completato con successo gli studi di fase 1 per il suo prodotto di punta, Zofin™, e ora sta cercando l'approvazione della FDA per varie malattie e condizioni croniche.
Il pipeline di prodotti di ZEO include Zofin™, derivato da fonti perinatali, e Patient Pure X™ (PPX™), un biologico autologo dal sangue periferico di un paziente. L'azienda sta anche sviluppando applicazioni topiche per la bellezza e anti-invecchiamento in collaborazione con Exotropin.
Con una proiezione di crescita del mercato del 22,8% all'anno nella medicina rigenerativa, ZEO mira a diventare un leader di settore nella terapia biologica. Recentemente, l'azienda ha cambiato nome da Organicell Regenerative Medicine per riflettere meglio il suo focus sulla ricerca scientifica.
ZEO ScientifiX (OTCQB:ZEOX), una compañía biofarmacéutica en etapa clínica con sede en el sur de Florida, está avanzando su programa de investigación hacia ensayos clínicos de fase 2. La compañía completó recientemente ensayos de fase 1 exitosos para su producto insignia, Zofin™, y ahora busca la aprobación de la FDA para diversas enfermedades y condiciones crónicas.
El portafolio de productos de ZEO incluye Zofin™, derivado de fuentes perinatales, y Patient Pure X™ (PPX™), un biológico autólogo de la sangre periférica de un paciente. La empresa también está desarrollando aplicaciones estéticas y anti-envejecimiento tópicas en asociación con Exotropin.
Con un crecimiento proyectado del mercado del 22,8% anual en medicina regenerativa, ZEO tiene como objetivo convertirse en un líder de la industria en terapias biológicas. Recientemente, la compañía cambió su nombre de Organicell Regenerative Medicine para reflejar mejor su enfoque en la investigación científica.
ZEO ScientifiX (OTCQB:ZEOX)는 플로리다 남부에 본사를 둔 임상 단계의 생명공학 회사로, 연구 프로그램을 2상 임상 시험으로 진행하고 있습니다. 이 회사는 최근 주력 제품인 Zofin™의 1상 임상 시험을 성공적으로 마쳤으며, 현재 다양한 질병과 만성 질환에 대한 FDA 승인을 요청하고 있습니다.
ZEO의 제품 파이프라인에는 조산원으로부터 유래한 Zofin™과 환자의 말초 혈액에서 추출한 자가 생물학적 제품인 Patient Pure X™ (PPX™)가 포함되어 있습니다. 또한 Exotropin과 협력하여 국소 미용 및 항노화 애플리케이션을 개발하고 있습니다.
재생 의학 분야에서 연평균 22.8%의 시장 성장이 예상되는 가운데, ZEO는 생물학적 치료 분야의 산업 리더가 되는 것을 목표로 하고 있습니다. 최근 이 회사는 과학 연구에 대한 초점을 더욱 잘 반영하기 위해 Organicell Regenerative Medicine에서 이름을 변경했습니다.
ZEO ScientifiX (OTCQB:ZEOX), une entreprise biopharmaceutique en phase clinique basée en Floride du Sud, fait avancer son programme de recherche vers des essais cliniques de phase 2. L'entreprise a récemment achevé avec succès des essais de phase 1 pour son produit phare, Zofin™, et cherche maintenant à obtenir l'approbation de la FDA pour diverses maladies et conditions chroniques.
Le pipeline de produits de ZEO comprend Zofin™, dérivé de sources périnatales, et Patient Pure X™ (PPX™), un biologique autologue provenant du sang périphérique d'un patient. L'entreprise développe également des applications esthétiques et anti-âge topiques en partenariat avec Exotropin.
Avec une croissance projetée du marché de 22,8 % par an dans le domaine de la médecine régénérative, ZEO vise à devenir un leader de l'industrie dans les thérapies biologiques. Récemment, l'entreprise a changé son nom d'Organicell Regenerative Medicine pour mieux refléter son accent sur la recherche scientifique.
ZEO ScientifiX (OTCQB:ZEOX), ein biopharmazeutisches Unternehmen in der klinischen Phase mit Sitz in Südflorida, entwickelt sein Forschungsprogramm weiter in Richtung Phase 2 klinischer Studien. Das Unternehmen hat kürzlich erfolgreiche Phase 1-Studien für sein Flaggschiffprodukt, Zofin™, abgeschlossen und sucht nun die FDA-Zulassung für verschiedene Krankheiten und chronische Erkrankungen.
Die Produktpipeline von ZEO umfasst Zofin™, das aus perinatalen Quellen gewonnen wird, sowie Patient Pure X™ (PPX™), ein autologes biologisches Produkt aus dem peripheren Blut eines Patienten. Das Unternehmen entwickelt auch topische ästhetische und anti-aging Anwendungen in Partnerschaft mit Exotropin.
Mit einem prognostizierten Marktwachstum von 22,8% jährlich im Bereich der regenerativen Medizin strebt ZEO an, ein Branchenführer in der biologischen Therapie zu werden. Das Unternehmen hat kürzlich seinen Namen von Organicell Regenerative Medicine geändert, um seinen Fokus auf die wissenschaftliche Forschung besser widerzuspiegeln.
- Successful completion of Phase 1 clinical trials for flagship product Zofin™
- Advancing towards Phase 2 clinical trials for multiple indications
- Partnership with Exotropin, for developing aesthetic and anti-aging applications
- Access to state-of-the-art cGMP compliant laboratory at Nova Southeastern University
- Projected market growth of 22.8% annually in regenerative medicine space
- None.
South Florida Biotech Company Seeks To Expand Its Research Program Into Phase 2 Clinical Trials
FORT LAUDERDALE, FL / ACCESSWIRE / September 24, 2024 / ZEO ScientifiX, Inc. ("ZEO" or the "Company") (OTCQB:ZEOX), a South Florida-based clinical-stage biopharmaceutical company, believes it is now poised to play a bigger role in the therapeutics market thanks to its rapidly-advancing research. ZEO recently completed successful Phase 1 clinical trials involving its flagship proprietary product, Zofin™. Now, the Company is actively seeking to launch Phase 2 trials for Zofin™ for several indications along with other products in the Company's pipeline. ZEO's goal is to obtain FDA approval for the use of its products for the treatment of various diseases and chronic conditions.
Ian Bothwell, Interim Chief Executive Officer at ZEO, stated "I am proud of our recent accomplishments and the fact that we are now actively working toward the commencement of Phase 2 clinical trials. This is a significant milestone that has invigorated our team and brought increased focus to achieving our Company's meaningful goals. We have eminently qualified researchers, an extremely experienced management team, and a state-of-the-art cGMP compliant laboratory located at Nova Southeastern University, which is considered one of the top research collaboration complexes in the country. We believe that we are uniquely positioned to become an industry leader in developing biologic therapeutics in this growing and expanding market." According to Precedence Research, the regenerative medicine space is expected to grow to a nearly
ZEO's research and development (R&D) product pipeline underscores the Company's commitment to innovation and its mission to advance the use of biologic therapies to address the unmet needs of patients facing acute and chronic conditions in multiple areas.
The Company's proprietary product, Zofin™, is derived from perinatal sources and manufactured to retain naturally occurring extracellular vesicles, proteins, and cell secreted nanoparticles. Its Patient Pure X™ ("PPX™") product is an autologous biologic containing a nanoparticle fraction that is precipitated from a patient's own peripheral blood.
In addition to its clinical trials research program to treat various diseases and chronic conditions, ZEO is seeking to develop new formulations for topical aesthetic and anti-aging applications. The Company has partnered with Exotropin, LLC ("Exotropin") to develop various products and technologies for these applications. Exotropin is a private company that has proprietary technology involving the use of topical exosomes and a diversified portfolio of skin and hair care products. ZEO also owns a minority interest in Exotropin.
During February of this year, the Company changed its name from Organicell Regenerative Medicine to ZEO ScientifiX, to better reflect the Company's mission and commitment to scientific research and the development of new biologic therapies.
Dr. George Shapiro, Chief Medical Officer at ZEO, stated "We believe that ZEO is on the cusp of major advancements in both regenerative and aesthetic products. Our unique approach and robust research and development pipeline position us for future substantial market impact, benefiting patients and providers alike."
For more information, or to schedule an interview, please contact Meieli Sawyer at msawyer@weinbachgroup.com or 305-668-0070.
About ZEO ScientifiX, Inc.
ZEO ScientifiX, Inc. (OTCQB: ZEOX) is a clinical-stage biopharmaceutical company located at Nova Southeastern University's Collaborative Center for Research. ZEO primarily focuses on the development of innovative biological therapeutics for the treatment of chronic diseases and the provision of related services. The Company's proprietary products are derived from allogenic and autologous sources and are manufactured in an FDA-registered, cGMP-compliant laboratory. To learn more, please visit https://zeoscientifix.com/
Forward-Looking Statements
Certain statements contained in this Report, including those regarding the Company's readiness to play a bigger role in the therapeutics market based on its rapidly advancing research and the Company's unique position of becoming an industry leader in developing biologic therapeutics should be considered forward-looking statements within the meaning of the Securities Act of 1933, as amended (the "Securities Act"), the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and the Private Securities Litigation Reform Act of 1995. These forward-looking statements are often identified by the use of forward-looking terminology such as "will," "believes," "expects," "potential," or similar expressions, involving known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, they do involve assumptions, risks and uncertainties, and these expectations may prove to be incorrect. No assurances can be given that the Company will be successful in its research initiatives. In addition, no assurances can be given that our research initiatives will increase the price of our common stock to a level that is attractive to brokerage houses and institutional investors. We remind you that actual results could vary dramatically as a result of known and unknown risks and uncertainties, including but not limited to: potential issues related to our financial condition, competition, the ability to retain key personnel, product safety, efficacy and acceptance, the commercial success of any new products or technologies, success of clinical programs, ability to retain key customers, our inability to expand sales and distribution channels, legislation or regulations affecting our operations including product pricing, reimbursement or access, the ability to protect our patents and other intellectual property both domestically and internationally, and other known and unknown risks and uncertainties, including the risk factors discussed in the Company's periodic reports that are filed with the SEC and available on the SEC's website (http://www.sec.gov). You are cautioned not to place undue reliance on these forward-looking statements. All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these risk factors. Specific information included in this Report may change over time and may or may not be accurate after the date of the release. ZEO has no intention and specifically disclaims any duty to update the information in this Report.
###
Contact Information
Meieli Sawyer
Director of Communications
msawyer@weinbachgroup.com
305-668-0070
SOURCE: ZEO ScientifiX, Inc.
View the original press release on accesswire.com
FAQ
What is ZEO ScientifiX's stock symbol?
What is ZEO ScientifiX's flagship product?
What is the projected market size for regenerative medicine by 2032?
What is Patient Pure X™ (PPX™)?
When did ZEO ScientifiX change its company name?
